Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
80.8M
-
Number of holders
-
123
-
Total 13F shares, excl. options
-
43M
-
Shares change
-
+1.98M
-
Total reported value, excl. options
-
$2.73B
-
Value change
-
+$129M
-
Put/Call ratio
-
0.03
-
Number of buys
-
73
-
Number of sells
-
-40
-
Price
-
$63.49
Significant Holders of Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR) as of Q4 2021
144 filings reported holding KYMR - Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q4 2021.
Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR) has 123 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43M shares
of 80.8M outstanding shares and own 53.24% of the company stock.
Largest 10 shareholders include Atlas Venture Life Science Advisors, LLC (6.88M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.55M shares), BlackRock Inc. (3.4M shares), BVF INC/IL (3.18M shares), VANGUARD GROUP INC (2.96M shares), WELLINGTON MANAGEMENT GROUP LLP (2.69M shares), Redmile Group, LLC (2.59M shares), BAKER BROS. ADVISORS LP (2.38M shares), FMR LLC (2.35M shares), and STATE STREET CORP (1.64M shares).
This table shows the top 123 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.